Cutera (NASDAQ:CUTR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cutera (NASDAQ:CUTR) in a research report sent to investors on Tuesday. The firm issued a sell rating on the medical device company’s stock.

Other research analysts also recently issued reports about the stock. Piper Sandler reissued a “neutral” rating and issued a $1.00 price target (down from $3.00) on shares of Cutera in a report on Friday, August 9th. Stephens dropped their price objective on Cutera from $10.00 to $5.00 and set an “overweight” rating for the company in a research note on Friday, August 9th.

Cutera Trading Up 16.6 %

Shares of Cutera stock opened at $0.46 on Tuesday. The company’s 50-day moving average price is $0.59 and its 200-day moving average price is $1.12. The company has a market cap of $9.23 million, a price-to-earnings ratio of -0.07 and a beta of 1.35. Cutera has a 12-month low of $0.28 and a 12-month high of $4.97.

Institutional Trading of Cutera

Several institutional investors and hedge funds have recently made changes to their positions in CUTR. Bayesian Capital Management LP bought a new position in Cutera in the first quarter valued at $33,000. Ground Swell Capital LLC bought a new position in shares of Cutera during the 2nd quarter valued at about $37,000. Bank of Montreal Can increased its position in shares of Cutera by 14.2% during the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after purchasing an additional 35,248 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of Cutera by 164.5% during the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after buying an additional 70,870 shares in the last quarter. Hedge funds and other institutional investors own 90.70% of the company’s stock.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.